Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19420075 | 1.00 | EPHX1 (0.46) | EPHX1MAPTKDM4ETHRBGPR119 | |
| SCHEMBL23762130 | 0.92 | MAPT (0.51) | EPHX1MAPTKDM4ETHRBGPR119 | |
| SCHEMBL24209476 | 0.89 | GPR119 (0.48) | EPHX1MAPTKDM4ETHRBGPR119 | |
| SCHEMBL625040 | 0.85 | MAPT (0.43) | EPHX1MAPTKDM4ETHRBGPR119 | |
| SCHEMBL19420078 | 0.80 | MAPT (0.48) | EPHX1MAPTKDM4ETHRBGPR119 | |
| SCHEMBL19420091 | 0.80 | MAPT (0.48) | EPHX1MAPTKDM4ETHRBGPR119 | |
| SCHEMBL5765921 | 0.80 | MAPT (0.48) | EPHX1MAPTKDM4ETHRBGPR119 | |
| SCHEMBL13654519 | 0.80 | MAPT (0.48) | EPHX1MAPTKDM4ETHRBGPR119 | |
| SCHEMBL31618659 | 0.80 | MAPT (0.46) | EPHX1MAPTKDM4ETHRBGPR119 | |
| SCHEMBL23580316 | 0.79 | MAPT (0.45) | EPHX1MAPTKDM4ETHRBGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220127265-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2022-04-28 | — | — | US | disclosed |
| US-20220127265-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2022-04-28 | — | — | US | disclosed |
| US-11247989-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-11247989-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| CN-109476663-B | Pyrazolopyridine derivatives for the treatment of cancer | 基因泰克公司 | 2021-11-09 | — | — | CN | disclosed |
| EP-3464286-B1 | PYRAZOLOPYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | GENENTECH INC (US) | 2021-08-18 | — | — | EP | disclosed |
| US-20190241558-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2019-08-08 | — | — | US | disclosed |
| US-20190241558-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2019-08-08 | — | — | US | disclosed |
| EP-3464286-A1 | PYRAZOLOPYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | Genentech, Inc. (US) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017205538-A1 | PYRAZOLOPYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| WO-2017205538-A1 | PYRAZOLOPYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11247989-B2 | Therapeutic compounds and uses thereof | EP300, HDAC1, CREBBP | EPHX1 1509/4885MAPT 2960/4885KDM4E 358/4885 |
| US-20190241558-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, CREBBP | EPHX1 1509/4885MAPT 2960/4885KDM4E 358/4885 |
| US-20220127265-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, CREBBP | EPHX1 1509/4885MAPT 2960/4885KDM4E 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.